Pluri Inc.

Plurilock Announces Payment of Debenture Interest

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved